GE Healthcare and Osprey Medical have signed a four-year agreement under which GE will distribute Osprey's DyeVert contrast minimization device in Europe, Russia, the Middle East, Africa, Central Asia, and Turkey.
The partnership will help clinicians minimize acute kidney injury complications after interventional coronary angiograms in patients with chronic kidney disease, according to GE. DyeVert reduces the amount of contrast in the kidney by about 40%, GE said.
